Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Short-term Investments: 2016-2025

Historic Short-term Investments for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $146.8 million.

  • Rocket Pharmaceuticals' Short-term Investments fell 13.67% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year decrease of 13.67%. This contributed to the annual value of $208.7 million for FY2024, which is 34.22% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Short-term Investments of $146.8 million as of Q3 2025, which was down 38.49% from $238.7 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Short-term Investments peaked at $317.3 million during Q4 2023, and registered a low of $109.9 million during Q3 2022.
  • Its 3-year average for Short-term Investments is $238.6 million, with a median of $240.2 million in 2024.
  • Its Short-term Investments has fluctuated over the past 5 years, first spiked by 150.44% in 2021, then plummeted by 37.51% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Short-term Investments (Quarterly) stood at $156.0 million in 2021, then soared by 38.34% to $215.9 million in 2022, then skyrocketed by 46.97% to $317.3 million in 2023, then crashed by 34.22% to $208.7 million in 2024, then dropped by 13.67% to $146.8 million in 2025.
  • Its Short-term Investments was $146.8 million in Q3 2025, compared to $238.7 million in Q2 2025 and $268.4 million in Q1 2025.